{
    "clinical_study": {
        "@rank": "36789", 
        "arm_group": {
            "arm_group_label": "Brentuximab Vedotin Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Brentuximab vedotin will be given intravenously with a dose of 1.8 mg/kg every 21 days, over 30 minutes for 16 cycles in the clinic."
        }, 
        "brief_summary": {
            "textblock": "The main purpose of this study is to test if brentuximab vedotin has an effect on cancer in\n      patients with a certain type of large B-cell lymphoma.  The side effects (unwanted effects)\n      of SGN-35 in patients with this certain type of large B-cell lymphoma will also be studied.\n      It is not known if brentuximab vedotin is better or worse than other treatment patients\n      might be given."
        }, 
        "brief_title": "Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral T-Cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, T-Cell", 
                "Lymphoma, T-Cell, Peripheral"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed diagnosis of PTCL expressing CD30 receptor. Diagnosis will be based on\n             identification of PTCL in biopsy specimens characterized by positivity for CD30\n             staining in the malignant cell population. Following PTCL subtypes will be eligible:\n             Peripheral T - cell lymphoma, not otherwise specified (NOS); Angioimmunoblastic\n             T-cell Lymphoma; Subcutaneous Panniculitis Like T-cell Lymphoma; Hepatosplenic\n             gamma/delta T cell Lymphoma; Extranodal natural killer (NK)T-cell Lymphoma, nasal\n             type; Enteropathy-associated T-cell lymphoma; Adult T-cell Leukemia/lymphoma; T-cell\n             prolymphocytic leukemia; Primary cutaneous gamma-delta T-cell lymphoma; Aggressive NK\n             cell leukemia; Epstein Barr Virus(EBV)-positive T-cell lymphoproliferative disorders\n             of childhood; Transformed mycosis fungoides who have progressed following treatment\n             with both methotrexate and bexarotene; Sezary syndrome\n\n          -  Histology slides and pathology material must be available at the site for each\n             patient before enrollment in order to be sent to the Leading Institution of the study\n             for central pathology review and pharmacodynamic studies.\n\n          -  Patients must have progressive, relapsed or refractory disease after: At least one\n             prior systemic anti-lymphoma regimen (chemotherapy or immunotherapy except for\n             transformed mycosis fungoides as described previously); Relapsed or failed autologous\n             or allogeneic stem cell transplant.\n\n          -  Understand and voluntarily sign an Institutional Review Board (IRB) approved informed\n             consent form\n\n          -  Must have at least one site of disease (index lesion) measurable in two dimensions by\n             computed tomography (CT)\n\n          -  Patients with leukemic form of PTCL who will not have a measurable lesion in two\n             dimensions by CT scan, relapsed or refractory disease must be detected by\n             immunohistochemistry or flow cytometry and molecular clonality studies in bone marrow\n             or peripheral blood.\n\n          -  At least 4 weeks since the last chemotherapy, radiation therapy, immunotherapy or any\n             investigational non-immunotherapy products\n\n          -  Must meet the following criteria within 4 days before the first dose of study drug:\n\n               -  Neutrophils \u22651,000/ul\n\n               -  Hemoglobin \u2265 8 g/dL\n\n               -  Platelets\u2265 50.0x10^9 /L\n\n               -  Total bilirubin \u2264 1.5 x upper normal limit, or \u2264 5 x upper normal limit if\n                  documented hepatic involvement with lymphoma or history of Gilbert's Syndrome\n\n               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 3 x upper\n                  normal limit (\u2264 5 x upper normal limit if documented hepatic involvement with\n                  lymphoma)\n\n               -  Calculated creatinine clearance \u2265 40 mL/min/1.73 m^2 based on Cockcroft and\n                  Gault method\n\n               -  PT or International Normalization Ratio (INR), and Activated Partial\n                  Thromboplastin Time (APTT) \u2264 1.5 x upper limit of normal unless patient is\n                  receiving anticoagulants. If patient is on anticoagulation therapy, levels\n                  should be within therapeutic range.\n\n               -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n\n               -  Negative pregnancy test for women of childbearing potential\n\n               -  Recovered (\u2264 Grade 1 toxicity) from the reversible effects of prior\n                  antineoplastic therapy\n\n        Exclusion Criteria:\n\n          -  Any of the following cardiovascular conditions or values within 6 months before the\n             first dose of study drug: Myocardial infarction and the New York Heart Association\n             (NYHA) Class III or IV heart failure\n\n          -  History of another primary malignancy not in remission for at least 3 years; except\n             adequately treated patients with completely resected in situ carcinoma, such as\n             nonmelanoma skin cancer and cervical carcinoma in situ on biopsy or a squamous\n             intraepithelial lesion on Pap smear, or localized prostate cancer with\n             prostate-specific antigen (PSA) <1 ng/ml\n\n          -  Known active cerebral/meningeal involvement with lymphoma. Asymptomatic patients with\n             previously treated and resolved central nervous system (CNS) lymphoma involvement are\n             permitted.\n\n          -  Prior administration of Brentuximab vedotin\n\n          -  Corticosteroid monotherapy for lymphoma within 2 weeks of the first dose of study\n             drug\n\n          -  Any serious underlying medical condition that, in the opinion of the investigator or\n             medical monitor, would impair the ability to receive or tolerate the planned\n             treatment\n\n          -  Known hypersensitivity to recombinant proteins, or any component contained in the\n             drug formulation\n\n          -  Female patients who are lactating or have a positive serum pregnancy test during the\n             screening period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01841021", 
            "org_study_id": "MCC-17343", 
            "secondary_id": "35-IST-019"
        }, 
        "intervention": {
            "arm_group_label": "Brentuximab Vedotin Treatment", 
            "description": "Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day 1 of every 21 day cycle.", 
            "intervention_name": "Brentuximab vedotin", 
            "intervention_type": "Drug", 
            "other_name": [
                "SGN-35", 
                "ADCETRISTM", 
                "antibody drug conjugate(ADC)", 
                "chemotherapy", 
                "monomethyl auristatin E (MMAE)"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Peripheral T-Cell Lymphoma (PTCL)", 
            "Relapsed", 
            "Refractory", 
            "CD30 Receptor", 
            "Large B-Cell Lymphoma"
        ], 
        "lastchanged_date": "April 15, 2014", 
        "link": {
            "description": "Moffitt Cancer Center Clinical Trials website", 
            "url": "http://www.moffitt.org/research--clinical-trials/clinical-trials"
        }, 
        "location": {
            "contact": {
                "email": "elyce.turba@moffitt.org", 
                "last_name": "Elyce Turba, MSN, RN", 
                "phone": "813-745-1706"
            }, 
            "facility": {
                "address": {
                    "city": "Tampa", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33612"
                }, 
                "name": "H. Lee Moffitt Cancer Center and Research Institute"
            }, 
            "investigator": [
                {
                    "last_name": "Lubomir Sokol, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Celeste Bello, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Bijal Shah, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 Receptor", 
        "overall_official": {
            "affiliation": "H. Lee Moffitt Cancer Center and Research Institute", 
            "last_name": "Lubomir Sokol, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the activity of Brentuximab vedotin in patients with relapsed/refractory Peripheral T cell Lymphoma (PTCL) expressing CD30 receptor. The ORR [complete response (CR)+ partial response (PR)] will be used as the primary endpoint to assess efficacy.The primary efficacy parameter is objective response rate, defined as the proportion of patients with complete response (CR) and partial response (PR). Follow-up assessments after cycle 16 will be done every 12 weeks for up to 24 months. Restaging imaging computed tomography (CT) scans will be repeated 12 and 24 months from the beginning of the follow-up period. Objective disease response (CR and PR) will be defined according to the modified 2007 International Working Group (IWG) response criteria for non-Hodgkin lymphomas (NHL). CR = Disappearance of all evidence of disease; PR = Regression of measurable disease and no new sites.", 
            "measure": "Overall Response Rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01841021"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Objective disease response (CR and PR), stable disease (SD) and progressive disease (PD) will be defined according to the modified 2007 International Working Group (IWG) response criteria for non-Hodgkin lymphomas (NHL).", 
                "measure": "Median Time to Response", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "description": "Objective disease response (CR and PR), stable disease (SD) will be defined according to the modified 2007 International Working Group (IWG) response criteria for non-Hodgkin lymphomas (NHL).", 
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "description": "Progressive disease (PD) will be defined according to the modified 2007 International Working Group (IWG) response criteria for non-Hodgkin lymphomas (NHL).", 
                "measure": "Median Time to Disease Progression", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "description": "Stable disease (SD) will be defined according to the modified 2007 International Working Group (IWG) response criteria for non-Hodgkin lymphomas (NHL).", 
                "measure": "Number of Participants with Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "description": "Radiological assessments will be discontinued at the time of tumor progression or initiation of new anticancer therapy, after which survival will be evaluated every 3 months until 2 years from the start of study treatment or until study closure.", 
                "measure": "Number of Participants with Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "description": "Adverse events (AEs) will be summarized by worst NCI NCI Common Terminology Criteria for Adverse Events (CTCAE) grade. The patient incidence of AEs will be summarized by system organ class, preferred term, severity and relationship to study drug. Adverse events leading to death or to discontinuation from treatment, events classified as CTCAE 4.0 grade 3 or higher, study-drug-related events, and serious adverse events (SAEs) will be listed separately.", 
                "measure": "Number of Participants with Study Related Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }
        ], 
        "source": "H. Lee Moffitt Cancer Center and Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Seattle Genetics, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "H. Lee Moffitt Cancer Center and Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}